Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets

References

• MurrayTJDiagnosis and treatment of multiple sclerosisBMJ200633252552716513709
   PubMed Web of Science ®Google Scholar
• LassmannHBruckWLucchinettiCFThe immunopathology of multiple sclerosis: an overviewBrain Pathol20071721021817388952
   PubMed Web of Science ®Google Scholar
• WeinshenkerBGThe natural history of multiple sclerosisNeurol Clin1995131191467739500
   PubMed Web of Science ®Google Scholar
• LublinFDReingoldSCDefining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple SclerosisNeurology1996469079118780061
   PubMed Web of Science ®Google Scholar
• KapposLFreedmanMSPolmanCHEffect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT studyLancet200737038939717679016
   PubMed Web of Science ®Google Scholar
• SbardellaETomassiniVGasperiniCNeutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective studyBMC Neurol200995419825153
   PubMed Web of Science ®Google Scholar
• WingerchukDMMultiple sclerosis disease-modifying therapies: adverse effect surveillance and managementExpert Rev Neurother2006633334616533138
   PubMed Web of Science ®Google Scholar
• LinkerRAKieseierBCGoldRIdentification and development of new therapeutics for multiple sclerosisTrends Pharmacol Sci20082955856518804288
   PubMed Web of Science ®Google Scholar
• KapposLAntelJComiGOral fingolimod (FTY720) in relapsing MS: 24-month results of the phase II studyN Engl J Med20063551124114016971719
   PubMed Web of Science ®Google Scholar
• KapposLRadueEWO’ConnorPA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med201036238740120089952
   PubMed Web of Science ®Google Scholar
• CohenJABarkhofFComiGOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med201036240241520089954
   PubMed Web of Science ®Google Scholar
• OckenfelsHMSchultewolterTOckenfelsGFunkRGoosMThe antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine networkBr J Dermatol19981393903959767281
   PubMed Web of Science ®Google Scholar
• SchimrigkSBruneNHellwigKOral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot studyEur J Neurol20061360461016796584
   PubMed Web of Science ®Google Scholar
• KapposLGoldRMillerDHMacmanusDGEfficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLancet20083721463147218970976
   PubMed Web of Science ®Google Scholar
• BruneauJMYeaCMSpinella-JeagleSPurification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomideBiochem1998J336299303
   Google Scholar
• KornTToykaKHartungHPJungSSuppression of experimental autoimmune neuritis by leflunomideBrain20011241791180211522581
   PubMed Web of Science ®Google Scholar
• KornTMagnusTToykaKJungSModulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide – mechanisms independent of pyrimidine depletionJ Leukoc Biol20047695096015328336
   PubMed Web of Science ®Google Scholar
• O’ConnorPWLiDFreedmannMSA phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapsesNeurology20066689490016567708
   PubMed Web of Science ®Google Scholar
• YangJSXuLYXiaoBGHedlundGLinkHLaquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGFβ in Lewis ratsJ Neuroimmunol20041563915465591
   PubMed Web of Science ®Google Scholar
• ComiGPulizziARovarisMEffect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLancet20083712085209218572078
   PubMed Web of Science ®Google Scholar
• CarsonDAWassonDBTaetleRYuASpecific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytesBlood1983627377436136305
   PubMed Web of Science ®Google Scholar
• LiliemarkJThe clinical pharmacokinetics of cladribineClin Pharmacokinet1997321201319068927
   PubMed Web of Science ®Google Scholar
• BeutlerESipeJCRomineJSThe treatment of chronic progressive multiple sclerosis with cladribineProc Natl Acad Sci U S A199693171617208643695
   PubMed Web of Science ®Google Scholar
• BeutlerENew chemotherapeutic agent: 2-chlorodeoxyadenosineSemin Hematol199431140457907189
   PubMed Web of Science ®Google Scholar
• RiceGPFilippiMComiGCladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study GroupNeurology2000541145115510720289
   PubMed Web of Science ®Google Scholar
• SchirmerMMurEPfeifferKPThalerJKonwalinkaGThe safety profile of low-dose cladribine in refractory rheumatoid arthritis. A pilot trialScand J Rheumatol1997263763799385350
   PubMed Web of Science ®Google Scholar
• RomineJSSipeJCKoziolJAZyroffJBeutlerEA double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosisProc Assoc Am Physicians199911135449893155
   PubMedGoogle Scholar
• GiovannoniGCookSComiGthe CLARITY study groupA placebo controlled Trial of Oral Cladribine for Multiple SclerosisN Engl J Med2010120 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• StelmasiakZSolskiJNowickiJJakubowskaBRybaMGriebPEffect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover studyMult Scler200915676777019482866
   PubMed Web of Science ®Google Scholar
• LeistTPVermerschPThe potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulationCurr Med Res Opin2007232667267617880754
   PubMed Web of Science ®Google Scholar
• RieckmannPGiovannoniGCookSDCladribine tablets in relapsing-remitting multiple sclerosis: study design of the 2-year, Phase IIIb CLARITY (CLAdRibine tablets Treating multiple sclerosis orallY) extension studyMult Scler14S161S162
   Google Scholar
• VigliettaVGreenbergSMikolDClinical development plan for cladribine tablets, an oral immunomodulator, for the treatment of multiple sclerosis (Meeting Abstract, Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis [ECTRIMS], Dusseldorf, Germany, 2009 Sep 9–12). [P439]Mult Scler15S126S1272009
   Google Scholar
• Merck Serono2009 Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis. Press release 2008-10-31. http://www.merckserono.net/corp.merckserono/en/images/20070124_en_tcm112_16812.pdf?Version=
   Google Scholar
• Di MatteoMRVariations in patients’ adherence to medical recommendations: a quantitative review of 50 years of researchMed Care20044220020915076819
   PubMed Web of Science ®Google Scholar
• KlauerTZettlUKCompliance, adherence, and the treatment of multiple sclerosisJ Neurol2008255Suppl 6879219300966
   PubMed Web of Science ®Google Scholar
• CohenBARieckmannPEmerging oral therapies for multiple sclerosisInt J Clin Pract2007611922193017784852
   PubMed Web of Science ®Google Scholar
• FallowfieldLAtkinsLCattSPatients’ preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancerAnn Oncol20061720521016239231
   PubMed Web of Science ®Google Scholar
• TwelvesCGollinsSGrieveRSamuelLA randomised crossover trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancerAnn Oncol20061723924516344278
   PubMed Web of Science ®Google Scholar
• KrukMESchwalbeNThe relation between intermittent dosing and adherence: preliminary insightsClin Ther2006281989199517296456
   PubMed Web of Science ®Google Scholar